
LRMR Stock Forecast & Price Target
LRMR Analyst Ratings
Bulls say
Larimar Therapeutics is viewed favorably because nomlabofusp targets the root cause of Friedreich’s ataxia by delivering frataxin to mitochondria, and the clinical package shows sustained biomarker improvement alongside meaningful functional signals in a disease with no approved disease-modifying treatment. The regulatory setup also looks constructive after the rolling BLA submission was completed, with priority review still anticipated and a potential launch framework supported by earlier FDA designations and supportive pre-BLA feedback. Financially, the company reported $129M in cash and equivalents, plus $200.4M in cash, cash equivalents, and marketable securities at end-1Q26, with runway into late-2Q27 or 2Q27, though financing risk and possible dilution remain near-term overhangs.
Bears say
Larimar Therapeutics is highly exposed to regulatory and clinical setbacks, since accelerated approval may still require additional data, longer studies, or label limitations that could weaken commercialization. Its outlook is also constrained by a single-product dependence on nomlabofusp, so any safety issue or discontinuation would severely impair the pipeline and valuation. On top of that, competition from Biogen’s Skyclarys and other gene therapies, plus the likely need for additional external funding, creates meaningful execution and financing risk that could delay or terminate development programs.
This aggregate rating is based on analysts' research of Larimar Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LRMR Analyst Forecast & Price Prediction
Start investing in LRMR
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Larimar Therapeutics Inc (LRMR) Forecast
LRMR Analyst Forecast & Price Prediction
Start investing in LRMR
Order type
Buy in
Order amount
Est. shares
0 shares